Soleno Therapeutics Inc Stock Price, News & Analysis

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced that CEO Anish Bhatnagar will participate in a fireside chat at the Guggenheim Healthcare Talks on April 3, 2023, at 10:10 AM Eastern Time. This event focuses on genomic medicines and rare diseases. Investors can access a live audio webcast as well as a replay of the discussion on the company's website. Soleno is actively developing innovative therapies for rare diseases, particularly its lead candidate, DCCR extended-release tablets, targeting Prader-Willi syndrome, which is in Phase 3 clinical trials.

Soleno Therapeutics (NASDAQ: SLNO) provided a corporate update and financial results for Q4 and full-year 2022. Enrollment in Study C602 for DCCR treatment of Prader-Willi syndrome is nearing completion, with top-line data expected by Q3 2023. The company secured a $60 million Securities Purchase Agreement with healthcare investors, with the first $10 million contingent upon the completion of enrollment. As of December 31, 2022, Soleno reported $14.6 million in cash. R&D expenses decreased to $15.3 million for the year, while net loss reduced to $24.1 million, or $2.87 per share. Strengthened funding enhances operational capability ahead of critical data announcements.

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, has announced that CEO Anish Bhatnagar will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on March 14, 2023, at 11:20 AM Eastern Time. This participation highlights Soleno's commitment to transparency and engagement with investors. The event will be accessible via a live audio webcast, available on the company’s website. Soleno specializes in developing novel therapeutics for rare diseases, with its lead candidate, DCCR, currently undergoing Phase 3 clinical trials for Prader-Willi syndrome.

Soleno Therapeutics (NASDAQ: SLNO) announced the publication of results from its Phase 3 DESTINY PWS trial for DCCR (Diazoxide Choline) Extended-Release tablets in treating Prader-Willi Syndrome (PWS) in the peer-reviewed Journal of Clinical Endocrinology and Metabolism. The promising trial outcomes have prompted the initiation of a randomized withdrawal phase in the ongoing extension study C602, potentially paving the way for a New Drug Application submission. PWS affects 1 in 15,000 births, marked by severe hunger and related health issues, underscoring the urgent need for effective treatments.

Soleno Therapeutics (SLNO) announced a funding agreement with Nantahala Capital, Abingworth, and Vivo Capital, securing up to $60 million. The agreement includes $10 million upfront and additional funds upon achieving positive clinical data for DCCR, its treatment for Prader-Willi Syndrome (PWS). DCCR is in a Phase 3 study targeting hyperphagia, a major symptom of PWS. The funding is set to enhance Soleno’s financial standing and support its New Drug Application submission.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported its third quarter 2022 corporate update and financial results. The company initiated a randomized withdrawal period for Study C602, assessing DCCR for Prader-Willi syndrome (PWS), with top-line data expected in the first half of 2023. Financially, cash at quarter-end stood at $19.8 million. Research and development expenses were $3.8 million, down from $5.0 million in 2021. Net loss narrowed to $6.1 million, or $0.76 per share, compared to $8.1 million in the prior year.

Soleno Therapeutics (NASDAQ: SLNO) announced the initiation of a randomized withdrawal period for Study C602, focusing on DCCR (Diazoxide Choline) Extended-Release tablets, aimed at treating Prader-Willi syndrome (PWS). This pivotal phase of the study involves 80 patients across 22 sites, evaluating the drug's efficacy against a placebo. Positive discussions with the FDA suggest that data could support a New Drug Application. DCCR, designed to relieve symptoms of PWS, has received both Orphan Drug and Fast Track designations.